公开(公告)号：US10046005B2

公开(公告)日：2018-08-14

申请号：US15234291

申请日：2016-08-11

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K31/353 ,  A61K31/7032 ,  A61K31/7072 ,  A61K31/726 ,  A61K45/06 ,  A61K47/48 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/7056 ,  A61K31/198 ,  A61K31/728 ,  A61K31/734 ,  A61K31/737 ,  A61K47/69

Abstract: A composition and associated method for treating a hepatitis C virus (HCV) infection in a subject who is human being. The composition includes: an anti-viral agent and/or a protease inhibitor; a polymerase inhibitor; one or more viral entry inhibitors; and one or more anti-fibrotic agents and/or anti-hemolytic agents including one or more Polyphenols and/or one or more Thiols. The composition may also include one or more sulfated oligosaccharide or non-anticoagulant glycosaminoglycans (GAGs). The method administers, to the subject, a therapeutic dose of the composition to treat the subject for the HCV infection.

公开(公告)号：US09950091B2

公开(公告)日：2018-04-24

申请号：US15001385

申请日：2016-01-20

Applicant: Deena S. Mousa ,  Shaker A. Mousa

Inventor： Deena S. Mousa ,  Shaker A. Mousa

IPC: A61K31/728 ,  A61K31/734 ,  A61L15/44 ,  A61K38/48 ,  A61K31/195 ,  A61K31/137 ,  A61K33/14 ,  A61L26/00 ,  A61L15/58 ,  A61L24/00 ,  A61L24/10

CPC classification number: A61L15/44 ,  A61K31/137 ,  A61K31/195 ,  A61K38/4833 ,  A61K45/06 ,  A61L15/58 ,  A61L24/0015 ,  A61L24/0094 ,  A61L24/106 ,  A61L26/0066 ,  A61L26/0076 ,  A61L26/008 ,  A61L26/0095 ,  A61L2300/402 ,  A61L2300/406 ,  A61L2300/412 ,  A61L2300/418 ,  A61L2400/04 ,  A61L2400/12 ,  A61L2430/34 ,  C12Y304/21005 ,  C08L5/04 ,  C08L5/08 ,  C08L77/04 ,  C08L35/04

Abstract: A composition and a method of applying the composition to a site on or within a body of a mammal. The composition includes a hydrogel matrix that includes at least one polymer cross linked, via ionic or covalent bonding, with both hyaluronic acid and alginic acid. The at least one polymer is chitosan, poly L-Lysine, or a combination thereof.

公开(公告)号：US09822190B2

公开(公告)日：2017-11-21

申请号：US15008947

申请日：2016-01-28

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K9/48 ,  C08B37/00 ,  A61K31/727 ,  A61K9/19 ,  A61K45/06 ,  A61K9/51 ,  C08B37/08

CPC classification number: C08B37/0075 ,  A61K9/19 ,  A61K9/5123 ,  A61K31/727 ,  A61K45/06 ,  C08B37/003

Abstract: A nano-composition that includes nanoparticles, a method of forming the nano-composition, and a method of using the composition. The nanoparticles include a polycationic polymer ionically bonded to one or more polyanionic Glycosaminoglycans (GAGs), wherein the polycationic polymer is chitosan, methylated chitosan, poly L-Lysine, or poly L-Arginine.

公开(公告)号：US09597351B2

公开(公告)日：2017-03-21

申请号：US14614496

申请日：2015-02-05

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K31/353 ,  A61K31/7056 ,  A61K31/7072 ,  A61K31/198 ,  A61K31/737 ,  A61K45/06 ,  A61K31/726 ,  A61K31/728 ,  A61K31/734 ,  A61K31/7032 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20

CPC classification number: A61K31/737 ,  A61K31/198 ,  A61K31/353 ,  A61K31/7056 ,  A61K31/7072 ,  A61K31/728 ,  A61K31/734 ,  A61K45/06 ,  A61K2300/00

Abstract: This disclosure concerns novel formulation and Nanoformulations as defined in the specification and compositions comprising combination of HCV protease and polymerase inhibitors, with or without interferon, along with anti-fibrotic/anti-hemolytic agents' combination of naturally driven Polyphenol/Thiols, and Non-anticoagulant GAGs. These compounds are effective antiviral agents, especially in inhibiting the function of the various genotypes of Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising nano-targeted delivery of novel nanoformulation containing combined composition for HCV and/or hepatic targeted delivery for improved efficacy and safety.

公开(公告)号：US09572831B2

公开(公告)日：2017-02-21

申请号：US14526660

申请日：2014-10-29

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K31/704 ,  A61K31/727 ,  A61K47/48 ,  A61K31/7068 ,  A61K33/24

CPC classification number: A61K31/727 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K47/6935 ,  A61K47/6937

Abstract: A nanoformulation that includes nanoparticles. Each nanoparticle includes a shell in which a glycosaminoglycan (GAG is encapsulated. The GAG is ionically or covalently bonded to the shell. The GAG is selected from the group consisting of sulfated non-anticoagulant heparin (SNACH), super-sulfated non-anticoagulant heparin (S-SNACH), and a combination thereof. The shell includes Poly (lactic-co-glycolic acid) (PLGA), Polyethylene Glycol (PEG)-PLGA, maleimide-PEG-PLGA, chitosan, chitosan-PLGA, methoxy-polyethyleneglycol-poly (lactide-co-glycolide) (MPEG-PLGA)-(maleimide-PEG-PLGA), PLGA-Polycaprolate, or calcium alginate. A method of using the nanoformulation to treat a cancer in a subject includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the cancer.

Abstract translation: 包括纳米颗粒的纳米制剂。 每个纳米颗粒包括壳聚糖，其中糖胺聚糖（GAG被封装），GAG离子或共价键合到壳上，GAG选自硫酸化非抗凝血剂肝素（SNACH），超硫酸化非抗凝血剂肝素 （S-SNACH）及其组合，壳包括聚（乳酸 - 共 - 乙醇酸）（PLGA），聚乙二醇（PEG）-PLGA，马来酰亚胺-PEG-PLGA，壳聚糖，壳聚糖-PLGA，甲氧基 - 聚乙二醇 - 聚（丙交酯 - 共 - 乙交酯）（MPEG-PLGA） - （马来酰亚胺-PEG-PLGA），PLGA-聚己内酯或藻酸钙。使用纳米制剂治疗受试者的癌症的方法包括向患者施用 治疗有效量的用于治疗癌症的纳米制剂。

公开(公告)号：US20160346308A1

公开(公告)日：2016-12-01

申请号：US15234291

申请日：2016-08-11

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K31/7056 ,  A61K9/20 ,  A61K9/00 ,  A61K31/353 ,  A61K31/726 ,  A61K47/48 ,  A61K9/16 ,  A61K31/7032 ,  A61K31/7072 ,  A61K45/06

CPC classification number: A61K31/7056 ,  A61K9/0053 ,  A61K9/1635 ,  A61K9/1647 ,  A61K9/1652 ,  A61K9/167 ,  A61K9/20 ,  A61K31/198 ,  A61K31/353 ,  A61K31/7072 ,  A61K31/728 ,  A61K31/734 ,  A61K31/737 ,  A61K45/06 ,  A61K47/6937 ,  A61K2300/00

Abstract: A composition and associated method for treating a hepatitis C virus (HCV) infection in a subject who is human being. The composition includes: an anti-viral agent and/or a protease inhibitor; a polymerase inhibitor; one or more viral entry inhibitors; and one or more anti-fibrotic agents and/or anti-hemolytic agents including one or more Polyphenols and/or one or more Thiols. The composition may also include one or more sulfated oligosaccharide or non-anticoagulant glycosaminoglycans (GAGs). The method administers, to the subject, a therapeutic dose of the composition to treat the subject for the HCV infection.

Abstract translation: 用于治疗人类受试者的丙型肝炎病毒（HCV）感染的组合物和相关方法。 组合物包括：抗病毒剂和/或蛋白酶抑制剂; 聚合酶抑制剂; 一种或多种病毒进入抑制剂; 和一种或多种抗纤维化剂和/或抗溶血剂，包括一种或多种多酚和/或一种或多种硫醇。 组合物还可以包括一种或多种硫酸化寡糖或非抗凝血糖胺聚糖（GAG）。 该方法向受试者施用治疗剂量的组合物以治疗受试者HCV感染。

公开(公告)号：US09289395B2

公开(公告)日：2016-03-22

申请号：US12947389

申请日：2010-11-16

Applicant: Paul J. Davis ,  Shaker A. Mousa

Inventor： Paul J. Davis ,  Shaker A. Mousa

IPC: A61K9/14 ,  A61K9/51 ,  A61K31/192 ,  A61K47/48 ,  B82Y5/00

CPC classification number: A61K9/5153 ,  A61K31/192 ,  A61K47/593 ,  A61K47/595 ,  A61K47/60 ,  A61K47/61 ,  A61K47/6935 ,  A61K47/6937 ,  B82Y5/00

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Abstract translation: 公开了治疗具有与血管发生相关的病症的受试者的方法，包括施用有效量的聚合物纳米颗粒形式的甲状腺激素激动剂，其部分激动剂或其拮抗剂，以促进或抑制受试者的血管生成。 还公开了甲状腺激素或甲状腺激素类似物的聚合形式的组合物。

公开(公告)号：US09272049B2

公开(公告)日：2016-03-01

申请号：US13156047

申请日：2011-06-08

Applicant: Maria Alexander-Bridges ,  Shaker A. Mousa ,  Paul J. Davis

Inventor： Maria Alexander-Bridges ,  Shaker A. Mousa ,  Paul J. Davis

IPC: A61K31/22 ,  A61K47/48

CPC classification number: G01N33/5023 ,  A61K47/58 ,  A61K47/593 ,  A61K47/60 ,  A61K47/61 ,  C12N15/1086

Abstract: Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins. Exemplary compositions include RGD-polyphenol conjugates via an ester linkage; polyphenol polymer conjugated to RGD analogs or mimetics; and RGD polymer conjugates linked to polyphenol.

Abstract translation: 本文提供了通过靶向选择的细胞外和细胞外蛋白质的RGD结合位点来预防和治疗与代谢综合征相关的疾病和危险因素的组合物和方法。 典型的组合物包括通过酯键的RGD-多酚共轭物; 与RGD类似物或模拟物缀合的多酚聚合物; 和与多酚连接的RGD聚合物缀合物。

公开(公告)号：US20150224134A1

公开(公告)日：2015-08-13

申请号：US14614496

申请日：2015-02-05

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K31/737 ,  A61K31/7072 ,  A61K31/728 ,  A61K31/198 ,  A61K31/734 ,  A61K31/7056 ,  A61K31/353

CPC classification number: A61K31/737 ,  A61K31/198 ,  A61K31/353 ,  A61K31/7056 ,  A61K31/7072 ,  A61K31/728 ,  A61K31/734 ,  A61K45/06 ,  A61K2300/00

Abstract: This disclosure concerns novel formulation and Nanoformulations as defined in the specification and compositions comprising combination of HCV protease and polymerase inhibitors, with or without interferon, along with anti-fibrotic/anti-hemolytic agents' combination of naturally driven Polyphenol/Thiols, and Non-anticoagulant GAGs. These compounds are effective antiviral agents, especially in inhibiting the function of the various genotypes of Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising nano-targeted delivery of novel nanoformulation containing combined composition for HCV and/or hepatic targeted delivery for improved efficacy and safety.

Abstract translation: 本公开涉及如本说明书中定义的新型制剂和纳米制剂，其包含具有或不具有干扰素的HCV蛋白酶和聚合酶抑制剂的组合以及天然驱动的多酚/硫醇与抗纤维化/抗溶血剂的组合的组合， 抗凝剂GAGs。 这些化合物是有效的抗病毒剂，特别是抑制丙型肝炎病毒（HCV）各种基因型的功能。 因此，本公开还涉及通过使用这些新化合物或包含纳米靶向递送含有用于HCV和/或肝靶向递送的组合组合物的新型纳米制剂的组合物来治疗HCV相关疾病或病症的方法，以提高功效和安全性。

公开(公告)号：US20150132399A1

公开(公告)日：2015-05-14

申请号：US14526660

申请日：2014-10-29

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K31/727 ,  A61K31/704 ,  A61K47/48

CPC classification number: A61K31/727 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K47/6935 ,  A61K47/6937

Abstract: A nanoformulation that includes nanoparticles. Each nanoparticle includes a shell in which a glycosaminoglycan (GAG is encapsulated. The GAG is ionically or covalently bonded to the shell. The GAG is selected from the group consisting of sulfated non-anticoagulant heparin (SNACH), super-sulfated non-anticoagulant heparin (S-SNACH), and a combination thereof. The shell includes Poly (lactic-co-glycolic acid) (PLGA), Polyethylene Glycol (PEG)-PLGA, maleimide-PEG-PLGA, chitosan, chitosan-PLGA, methoxy-polyethyleneglycol-poly (lactide-co-glycolide) (MPEG-PLGA)-(maleimide-PEG-PLGA), PLGA-Polycaprolate, or calcium alginate. A method of using the nanoformulation to treat a cancer in a subject includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the cancer.

Abstract translation: 包括纳米颗粒的纳米制剂。 每个纳米颗粒包括壳聚糖，其中糖胺聚糖（GAG被封装），GAG离子或共价键合到壳上，GAG选自硫酸化非抗凝血剂肝素（SNACH），超硫酸化非抗凝血剂肝素 （S-SNACH）及其组合，壳包括聚（乳酸 - 共 - 乙醇酸）（PLGA），聚乙二醇（PEG）-PLGA，马来酰亚胺-PEG-PLGA，壳聚糖，壳聚糖-PLGA，甲氧基 - 聚乙二醇 - 聚（丙交酯 - 共 - 乙交酯）（MPEG-PLGA） - （马来酰亚胺-PEG-PLGA），PLGA-聚己内酯或藻酸钙。使用纳米制剂治疗受试者的癌症的方法包括向患者施用 治疗有效量的用于治疗癌症的纳米制剂。